Clinical Trial Update: p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update evaluating the p53MVA vaccine in combination with gemcitabine hydrochloride for recurrent ovarian epithelial cancer (also includin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Gemcitabine hydrochloride (Gemcitabine hydrochloride)
• p53MVA vaccine (p53MVA vaccine)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Recurrent Ovarian Epithelial Cancer, Recurrent Fallopian Tube Carcinoma | Phase 1 | Status: COMPLETED